NeuroSymbiosis: Next-Generation Neural Interface Systems

Publication ID: 24-11857326_0005_PTD
Published: November 07, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “NeuroSymbiosis: Next-Generation Neural Interface Systems,” Published Technical Disclosure No. 24-11857326_0005_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857326_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,326.

Summary of the Inventive Concept

NeuroSymbiosis is a revolutionary neural interface technology that enables seamless, real-time communication between the human brain and AI-powered systems, facilitating personalized therapy and enhancing cognitive performance.

Background and Problem Solved

The original patent's neural probes, while innovative, still have limitations in terms of invasiveness, tissue damage, and limited data analysis capabilities. NeuroSymbiosis addresses these limitations by introducing miniaturized, swarm-capable probes, nanoscale sensors and actuators, and cloud-based AI platforms for real-time data analysis and personalized therapy recommendations.

Detailed Description of the Inventive Concept

NeuroSymbiosis consists of a plurality of miniaturized neural probes, each integrated with a network of nanoscale sensors and actuators. These probes can be injected into the brain and wirelessly controlled by a patient or caregiver, enabling real-time data transmission and personalized therapy. The system also includes a cloud-based AI platform for data analysis and recommendations, as well as a virtual reality feedback system for enhancing cognitive performance and neural plasticity. The neural interface device features a flexible, conformable substrate, high-density nanoscale electrodes, and a self-healing, bio-compatible coating to minimize tissue damage and inflammation.

Novelty and Inventive Step

The NeuroSymbiosis system introduces several novel and non-obvious features, including the use of swarm-capable probes, nanoscale sensors and actuators, and cloud-based AI platforms for real-time data analysis and personalized therapy recommendations. These advancements enable a new level of precision, flexibility, and adaptability in neural interface technology.

Alternative Embodiments and Variations

Alternative embodiments of NeuroSymbiosis could include the use of different materials or geometries for the neural probes, varying the density and arrangement of the nanoscale sensors and actuators, or incorporating additional features such as neural stimulation or recording capabilities. Variations could also include the development of specialized probes for specific neurological disorders or applications.

Potential Commercial Applications and Market

NeuroSymbiosis has significant commercial potential in the neural interface market, with applications in neurology, psychiatry, and cognitive enhancement. The technology could be used to treat a range of neurological disorders, including epilepsy, Parkinson's disease, and depression, as well as enhance cognitive performance in healthy individuals.

Field of Art

Biomedical engineering, neural interface technologies, with a focus on minimally invasive neural probe design and agent delivery systems for neurological interventions

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or neurotechnology researcher with expertise in neural probe design, materials science, microelectronics, and biocompatible device fabrication, typically holding a PhD or equivalent advanced engineering experience

Obviousness Rationale

A PHOSITA would recognize that the NeuroSymbiosis system represents a predictable extension of existing neural probe technologies, applying known miniaturization, wireless communication, and AI-assisted medical device strategies to the foundational neural electrode design disclosed in the source patent. The core innovations involve integrating existing technologies in a novel configuration that addresses known limitations in neural interface systems, such as tissue damage and limited therapeutic capabilities.

Obvious Combinations & Variations

Source Patent Element
Dissolvable agent delivery structure for neural electrodes
PTD Variation
Nanoscale sensors and actuators integrated into neural probes for personalized therapy delivery
Obviousness Reasoning
A PHOSITA would find it obvious to enhance agent delivery mechanisms with smart sensor networks, as both serve the common goal of targeted neurological intervention using predictable microelectronic integration techniques
Source Patent Element
Electrode body with treatment agent capabilities
PTD Variation
Cloud-based AI platform for real-time data analysis and personalized therapy recommendations
Obviousness Reasoning
Extending treatment agent delivery with data-driven personalization represents a logical progression using known machine learning and medical monitoring technologies
Source Patent Element
Neural probe with minimized tissue damage design
PTD Variation
Flexible, conformable substrate with self-healing, bio-compatible coating
Obviousness Reasoning
Improving neural probe biocompatibility through advanced materials is a predictable solution to the source patent's tissue damage concerns, utilizing well-established materials engineering principles
Source Patent Element
Electrode array with treatment agent release
PTD Variation
Swarm-capable neural probes with wireless control and modular 3D-printed neural scaffolds
Obviousness Reasoning
Implementing distributed, controllable neural interfaces is an obvious technological progression using standard microelectronics and robotics design principles
Source Patent Element
Cannabinoid-based treatment agent delivery
PTD Variation
Virtual reality feedback system for enhancing cognitive performance and neural plasticity
Obviousness Reasoning
Expanding therapeutic neural interface capabilities through integrated sensory feedback represents a predictable innovation using established neurotechnology design approaches
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857326 and the disclosed technical variations, a person having ordinary skill in the art would find the claimed neural interface innovations obvious and anticipated, as the NeuroSymbiosis system represents a straightforward combination of known techniques in neural probe design, wireless communication, and personalized medical technologies, thereby rendering subsequent claims of novelty invalid under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,326
TitleAgent-delivering neural probe devices and related systems and methods
Assignee(s)NeuroOne Medical Technologies Corporation